Literature DB >> 20825351

Letting sleeping dos lie: does dormancy play a role in tuberculosis?

Michael C Chao1, Eric J Rubin.   

Abstract

Mycobacterium tuberculosis, which causes tuberculosis, remains a major human public health threat. This is largely due to a sizeable reservoir of latently infected individuals, who may relapse into active disease decades after first acquiring the infection. Furthermore, patients have a very slow response to treatment of active disease. Latency and antibiotic tolerance are commonly taken as a proxy for dormancy, a stable nonreplicative state. However, latency is a clinical term that is solely defined by a lack of disease indicators. The actual state of the bacterium in human latency is not well understood. Here we evaluate the results of several in vitro models of dormancy and consider the applicability of various animal models for studying aspects of human latency and resistance to killing by antibiotics. Furthermore, we propose a model for the initiation of dormancy and resuscitation during infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20825351     DOI: 10.1146/annurev.micro.112408.134043

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  90 in total

Review 1.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  Essentiality of DevR/DosR interaction with SigA for the dormancy survival program in Mycobacterium tuberculosis.

Authors:  Uma S Gautam; Kriti Sikri; Atul Vashist; Varshneya Singh; Jaya S Tyagi
Journal:  J Bacteriol       Date:  2013-12-06       Impact factor: 3.490

3.  New 2-thiopyridines as potential candidates for killing both actively growing and dormant Mycobacterium tuberculosis cells.

Authors:  Elena Salina; Olga Ryabova; Arseny Kaprelyants; Vadim Makarov
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

4.  The in vivo environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria.

Authors:  Obolbek Turapov; Sarah Glenn; Bavesh Kana; Vadim Makarov; Peter W Andrew; Galina V Mukamolova
Journal:  Am J Respir Crit Care Med       Date:  2014-12-15       Impact factor: 21.405

5.  Estimating the mutation rate of Mycobacterium tuberculosis during infection.

Authors:  David R Sherman; Sebastien Gagneux
Journal:  Nat Genet       Date:  2011-05       Impact factor: 38.330

Review 6.  How sisters grow apart: mycobacterial growth and division.

Authors:  Karen J Kieser; Eric J Rubin
Journal:  Nat Rev Microbiol       Date:  2014-07-07       Impact factor: 60.633

7.  23S rRNA as an a-Maz-ing new bacterial toxin target.

Authors:  Jason M Schifano; Nancy A Woychik
Journal:  RNA Biol       Date:  2014-02-07       Impact factor: 4.652

Review 8.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

9.  A Universal Stress Protein That Controls Bacterial Stress Survival in Micrococcus luteus.

Authors:  Spencer Havis; Abiodun Bodunrin; Jonathan Rangel; Rene Zimmerer; Jesse Murphy; Jacob D Storey; Thinh D Duong; Brandon Mistretta; Preethi Gunaratne; William R Widger; Steven J Bark
Journal:  J Bacteriol       Date:  2019-11-20       Impact factor: 3.490

10.  CarD integrates three functional modules to promote efficient transcription, antibiotic tolerance, and pathogenesis in mycobacteria.

Authors:  Ashley L Garner; Leslie A Weiss; Ana Ruiz Manzano; Eric A Galburt; Christina L Stallings
Journal:  Mol Microbiol       Date:  2014-07-16       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.